Reviewing Alder BioPharmaceuticals (NASDAQ:ALDR) & Its Competitors

Alder BioPharmaceuticals (NASDAQ: ALDR) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Alder BioPharmaceuticals to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, profitability and analyst recommendations.

Volatility and Risk

Alder BioPharmaceuticals has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals’ peers have a beta of 2.51, meaning that their average stock price is 151% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Alder BioPharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alder BioPharmaceuticals 0 1 11 0 2.92
Alder BioPharmaceuticals Competitors 960 3408 11912 239 2.69

Alder BioPharmaceuticals currently has a consensus price target of $30.25, indicating a potential upside of 68.99%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.19%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Alder BioPharmaceuticals is more favorable than its peers.

Valuation and Earnings

This table compares Alder BioPharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alder BioPharmaceuticals $110,000.00 -$156.25 million -3.33
Alder BioPharmaceuticals Competitors $290.27 million $35.99 million 53.59

Alder BioPharmaceuticals’ peers have higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Alder BioPharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alder BioPharmaceuticals N/A -93.14% -84.14%
Alder BioPharmaceuticals Competitors -6,408.55% -84.01% -35.63%

Institutional and Insider Ownership

96.8% of Alder BioPharmaceuticals shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.6% of Alder BioPharmaceuticals shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alder BioPharmaceuticals peers beat Alder BioPharmaceuticals on 8 of the 13 factors compared.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply